Fighting dengue, where Sanofi stumbled, Takeda treads carefully

23 November 2022

A new dengue vaccine, first approved in Indonesia, is to be evaluated by the US Food and Drug Administration under its Priority Review scheme.

Developed by Japanese pharma major Takeda (TYO:4502), TAK-003 is designed to prevent dengue disease caused by any dengue virus serotype in people aged between four and 60.

Marketed in Indonesia as Qdenga, the jab is part of a broad regulatory push from Takeda, with regulators at the European Medicines Agency already looking into an extensive data package.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK